The Pharma Data

JUNE 19, 2023

The findings bolster the idea, which is currently under investigation in at least three clinical trials, that when it comes to treating resistant breast cancer, two drugs may be better than one.

Drugs 40

Drugs HR Scientist Hormones 40

XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients.

Research 40

Research Clinical Trials Clinical Trials Trials 40

The Pharma Data

OCTOBER 26, 2020

I am confident in our ability to advance our promising pipeline and clinical trials despite the challenging environment, and I believe that our leadership and track record of solid commercial execution will continue to drive long-term growth.”. Sales. Sales. Financial Summary.

Sales 40

Sales Vaccination Vaccine Production 40

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer.

HR 52

HR Medicine Hormones Trials 52

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

The Pharma Data

JANUARY 10, 2021

By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?. . •. ?. . .

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246